Literature DB >> 3133990

Sodium cromoglycate in asthma: correlation between response and serum concentrations.

Y Yahav1, S Dany, D Katznelson, Z Farfel.   

Abstract

The clinical response to sodium cromoglycate treatment was compared with its concentration in serum. Twenty five children with asthma entered a 10 week trial of two baseline weeks followed by eight weeks of treatment by the inhalation of 20 mg of sodium cromoglycate spincaps four times a day. Individual clinical response was determined by the differences between baseline and treatment periods of: (a) percentage of symptomless days (delta score 0); (b) diary derived daily score for four symptoms (delta DS); and (c) peak expiratory flow rate (delta PEFR). At the end of the treatment period, patients inhaled a 20 mg spincap of sodium cromoglycate and the technique of inhalation was graded. Concentrations of sodium cromoglycate in serum were measured by radioimmunoassay in samples withdrawn 5 to 120 minutes after inhalation. Delta Score 0, delta DS, and delta PEFR correlated significantly with the area under the concentration time curve. Both the area under the sodium cromoglycate concentration time curve and clinical response correlated significantly with inhalation technique score. We suggest that response of children with asthma to inhalation treatment with sodium cromoglycate is correlated to its serum concentrations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3133990      PMCID: PMC1778889          DOI: 10.1136/adc.63.6.592

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  11 in total

1.  Spacing devices and metered-dose inhalers in childhood asthma.

Authors:  H Levison; P A Reilly; G H Worsley
Journal:  J Pediatr       Date:  1985-11       Impact factor: 4.406

2.  Cromolyn: past, present, and future.

Authors:  B A Berman
Journal:  Pediatr Clin North Am       Date:  1983-10       Impact factor: 3.278

3.  Controlled trial of cromoglycate and slow-release aminophylline in perennial childhood asthma.

Authors:  A T Edmunds; F Carswell; P Robinson; A O Hughes
Journal:  Br Med J       Date:  1980-09-27

4.  A double-blind study comparing the effectiveness of cromolyn sodium and sustained-release theophylline in childhood asthma.

Authors:  C T Furukawa; G G Shapiro; C W Bierman; M J Kraemer; D J Ward; W E Pierson
Journal:  Pediatrics       Date:  1984-10       Impact factor: 7.124

5.  The place of cromolyn sodium in the long-term management of childhood asthma based on a 3- to 5-year follow-up.

Authors:  S Godfrey; L Balfour-Lynn; P König
Journal:  J Pediatr       Date:  1975-09       Impact factor: 4.406

6.  Long-term trial of disodium cromoglycate and isoprenaline in children with asthma.

Authors:  M Silverman; N M Connolly; L Balfour-Lynn; S Godfrey
Journal:  Br Med J       Date:  1972-08-12

7.  Comparison of nebulised sodium cromoglycate and oral theophylline in controlling symptoms of chronic asthma in pre-school children: a double blind study.

Authors:  C J Newth; C V Newth; J A Turner
Journal:  Aust N Z J Med       Date:  1982-06

Review 8.  Cromolyn sodium: a review.

Authors:  G G Shapiro; P König
Journal:  Pharmacotherapy       Date:  1985 May-Jun       Impact factor: 4.705

9.  Cromolyn sodium in the treatment of asthma: coming of age in the United States.

Authors:  I L Bernstein
Journal:  J Allergy Clin Immunol       Date:  1985-08       Impact factor: 10.793

10.  Radioimmunoassay of sodium cromoglycate in human plasma.

Authors:  K Brown; J J Gardner; W J Lockley; J R Preston; D J Wilkinson
Journal:  Ann Clin Biochem       Date:  1983-01       Impact factor: 2.057

View more
  2 in total

1.  Plasma concentrations of disodium cromoglycate after various inhalation methods in healthy subjects.

Authors:  Y Kato; K Muraki; M Fujitaka; N Sakura; K Ueda
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

2.  Intermediary quantitative traits--an alternative in the identification of disease genes in asthma?

Authors:  M Sargurupremraj; K Pukelsheim; T Hofer; M Wjst
Journal:  Genes Immun       Date:  2013-10-17       Impact factor: 2.676

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.